Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22377126 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
Condition: Breast Cancer
Interventions: Drug: Standard chemotherapy;   Drug: bevacizumab [Avastin];   Drug: trastuzumab [Herceptin]

Indicates status has not been verified in more than two years